PharmAthene declares Development Progress to SparVax vaccine

The Company has completed testing and released the final drug product of sparvax for further clinical evaluation.

PharmAthene’s rPA technology platform uses E.Coli, a technology which increases manufacturing to produce more than 150 million rPA vaccines.

PharmAthene’s rPA anthrax vaccine program has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health and the Biomedical Advanced Research and Development Authority.

SparVax Executive Vice President and Chief Scientific Officer Thomas Fuerst said,"This latest achievement represents another major step forward for our SparVax program."